Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase I

Treatment

Active

18 to 85

Pharmaceutical / Industry

A5021004
NCT00607048

Trial Description

Summary

This is a dose-finding study; therefore, there is no hypothesis testing

Eligibility Criteria

Inclusion Criteria:

Patients with metastatic solid tumors, for whom carboplatin and paclitaxel are appropriate;

Patients >18 years of age;

Good performance status;

Adequate bone marrow and organ function

Exclusion Criteria:

Previous treatment with any other compound that targets CD40

Current or planned concurrent treatment with any anticancer agent;

Patients who have received bone marrow transplant;

History of autoimmune disorder

History (within the previous year) of heart failure or heart attack

Cancer-associated coagulation disorders

Trial Contact Information

Trial Lead Organizations/Sponsors

Pfizer Incorporated

Pfizer CT.gov Call Center

Study Director

Pfizer Oncology Clinical Trial Information Service		Ph: 1-877-369-9753
		Email: PfizerCancerTrials@emergingmed.com

Pfizer CT.gov Call Center

Ph: 1-800-718-1021

Trial Sites

U.S.A.

Pennsylvania

Philadelphia

Pfizer Investigational Site

Texas

San Antonio

Pfizer Investigational Site

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00607048
Information obtained from ClinicalTrials.gov on October 01, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.